Management of Basilar Ground Glass Opacities with Pancytopenia

Immediate Diagnostic Priorities

The American Society of Hematology recommends immediately excluding infectious causes, particularly Pneumocystis pneumonia and tuberculosis, while investigating for underlying hematologic malignancy or drug-induced processes in patients with basilar ground glass opacities and pancytopenia 1, 2, 3
Obtain sputum cultures, acid-fast bacilli smears, and nucleic acid amplification testing for tuberculosis immediately, as TB must be excluded first in any patient with this presentation 3
Send bronchoalveolar lavage for Pneumocystis jirovecii PCR and fungal cultures, since diffuse bilateral perihilar infiltrates with patchy ground-glass attenuation suggest Pneumocystis pneumonia in immunocompromised patients 2, 4
Start empiric trimethoprim-sulfamethoxazole 20 mg/kg/day if clinical suspicion for Pneumocystis is high, without waiting for confirmatory testing 5

Order high-resolution CT with both inspiratory and expiratory views to assess for mosaic attenuation and air-trapping, which helps differentiate hypersensitivity pneumonitis from infectious causes 3
Look for the "three-density pattern" (hypoattenuating, normal, and hyperattenuating lobules in close proximity), which is highly specific for fibrotic hypersensitivity pneumonitis 3, 6
Centrilobular nodules with ground-glass opacity affecting all lung zones suggests hypersensitivity pneumonitis in the appropriate clinical context 3

In immunocompromised patients with pancytopenia, diffuse infection becomes the second most likely diagnosis after pulmonary edema 2
Conventional chest radiographs show abnormalities in <2% of febrile neutropenic patients, making high-resolution CT essential 2
Nodular or cavitary lesions suggest invasive filamentous fungal infection, though differential includes Nocardia, Pseudomonas aeruginosa, or mycobacteria 2
Start mold-active systemic antifungal agents empirically if CT findings suggest invasive fungal disease, as pre-emptive treatment improves clinical outcome 2

If hypersensitivity pneumonitis is suspected, obtain detailed exposure history to organic antigens and perform BAL with lymphocyte differential; >20% lymphocytes supports hypersensitivity pneumonitis diagnosis 3
If drug-related pneumonitis is suspected, review all medications started 3-12 weeks prior to symptom onset and discontinue the offending agent immediately 3, 6
In patients with hairy cell leukemia or other hematologic malignancies causing pancytopenia, consider BRAF inhibitors as "off-label" therapy to achieve early granulocyte recovery and enable infection control 1

Do not assume infectious etiology without considering hypersensitivity pneumonitis, especially in nonsmokers with relevant exposure history 3
Do not delay tuberculosis evaluation in any patient with this presentation, regardless of geographic location or perceived risk 3
Do not overlook recent medication changes, as drug-related pneumonitis commonly occurs 3-12 weeks after drug initiation 3
In patients with extensive ground glass opacity (>30% of lung involvement), do not diagnose idiopathic pulmonary fibrosis; this pattern argues strongly for alternative diagnoses such as organizing pneumonia, hypersensitivity pneumonitis, or infection 3, 4

Proceed urgently to bronchoscopy with BAL when high clinical suspicion for Pneumocystis or fungal infection exists, or when CT shows nodular lesions or the "halo sign" suggesting invasive mold infection 2
Transbronchial biopsy combined with BAL increases diagnostic yield, particularly when fibrotic hypersensitivity pneumonitis is suspected 3